Skip to main content

Gergely Toth, PhD

Chief Executive Officer at Cantabio Pharmaceuticals

Location: Palo Alto, CA United States

Dr. Tóth is the CEO and founder of Cantabio Pharmaceuticals. He is also affiliated with the School of Pharmacy at University College London (UK) as an honorary associate professor and with the Research Center for Natural Sciences (Hungary) as the head of the research group for neurodegenerative disease drug discovery. Dr. Tóth is a scientist and a business professional with a long-term focus on developing therapeutics for neurodegenerative diseases. He holds a PhD from the department of biomedical sciences at Creighton University (2001), and an Executive MBA from the Judge Business School at the University of Cambridge (2012). He conducted postdoctoral studies at the department of molecular biology at the University of California, Berkeley (US). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the United States, where he mostly pursued drug discovery research for Parkinson’s and Alzheimer’s diseases.

Associated Grants

  • Development of Small-molecule Inhibitors that Reduce the Aggregation of Tau for the Treatment of Parkinson’s Disease


  • Developing Assays to Quantify Cys106 of DJ-1 in Distinct Oxidized States as a Potential Diagnostic Tool for Parkinson’s Disease


  • Determination of the 3D Structure of Biologically Active Small Molecules in Complex with DJ-1


  • Identification of Small-molecule Stabilizers of DJ-1: Biophysical and Cellular Validation


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.